Darunavir Hydrate

The dosage of Darunavir Hydrate for adults depends heavily on whether the patient has previously taken HIV medications and whether their virus has specific resistance mutations.

• Treatment-Naive Adults: The standard recommended dose is 800 mg (one 800 mg tablet) taken once daily with a booster (either 100 mg of ritonavir or 150 mg of cobicistat). This must be taken with food.
• Treatment-Experienced Adults (No Darunavir Resistance): If the patient has no known resistance mutations to Darunavir, the 800 mg once-daily dose with a booster is often sufficient.
• Treatment-Experienced Adults (With Darunavir Resistance): For patients with at least one Darunavir resistance-associated substitution or those who have failed multiple protease inhibitor treatments, the dose is typically 600 mg taken twice daily with 100 mg of ritonavir. Cobicistat is not recommended for twice-daily dosing regimens.

Darunavir Hydrate is approved for children 3 years of age and older who weigh at least 10 kg (approximately 22 lbs). Dosing in children is strictly weight-based:

• 10 kg to < 15 kg: 20 mg/kg of oral suspension with 40 mg of ritonavir twice daily.
• 15 kg to < 30 kg: 375 mg (tablet or suspension) with 50 mg of ritonavir twice daily.
• 30 kg to < 40 kg: 450 mg with 60 mg of ritonavir twice daily.
• 40 kg and above: Adult dosing may be considered (600 mg twice daily or 800 mg once daily depending on resistance).

Note: Darunavir is not approved for use in infants under 3 years of age due to the risk of severe toxicity observed in animal studies.

Renal Impairment

For patients with kidney disease, Darunavir Hydrate generally does not require a dose adjustment because very little of the drug is cleared through the kidneys. However, if Darunavir is used in a combination pill containing tenofovir, renal monitoring is essential, and the combination may be contraindicated in severe renal failure.

Hepatic Impairment

• Mild to Moderate (Child-Pugh A or B): No dose adjustment is typically required, but patients should be monitored closely for signs of liver toxicity.
• Severe (Child-Pugh C): Darunavir Hydrate is not recommended for use in patients with severe liver impairment.

Elderly Patients

Clinical trials did not include enough patients over 65 to determine if they respond differently. In general, dosing for elderly patients should be cautious, starting at the lower end of the range, reflecting the higher frequency of decreased hepatic, renal, or cardiac function.

1. 1With Food: You MUST take Darunavir Hydrate with a meal or a substantial snack. The type of food does not matter, but the presence of food is vital for the drug to be absorbed into your system.
2. 2Consistency: Take your dose at the same time(s) every day to maintain a steady level of the drug in your blood. This prevents the virus from replicating and developing resistance.
3. 3Swallow Whole: Tablets should be swallowed whole with water. Do not crush or chew the tablets unless specifically instructed by your pharmacist.
4. 4Storage: Store the medication at room temperature (68°F to 77°F or 20°C to 25°C). Keep the bottle tightly closed and protect it from moisture.

If you miss a dose, timing is critical:

• Once-Daily Regimen: If you remember within 12 hours of the missed dose, take it immediately with food. If more than 12 hours have passed, skip the dose and take the next one at the regular time.
• Twice-Daily Regimen: If you remember within 6 hours of the missed dose, take it immediately with food. If more than 6 hours have passed, skip the dose and take the next one at the regular time.
• Never Double Dose: Do not take two doses at once to make up for a missed one.

Symptoms of a Darunavir overdose are not well-documented but may include severe nausea, abdominal pain, or an intensification of side effects. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately. There is no specific antidote for Darunavir; treatment consists of general supportive measures, including monitoring of vital signs.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to drug resistance.

Most patients taking Darunavir Hydrate experience some side effects, especially during the first few weeks of treatment as the body adjusts to the medication. Common reactions include:

• Diarrhea: This is the most frequently reported side effect. It is usually mild to moderate but can be persistent. Staying hydrated is essential.
• Nausea and Vomiting: Often occurring shortly after taking the dose, these symptoms can frequently be managed by ensuring the drug is taken with a full meal.
• Headache: Mild tension-type headaches are common and usually resolve over time.
• Abdominal Pain: General discomfort or cramping in the stomach area.
• Rash: A mild-to-moderate skin rash may occur. If the rash is accompanied by fever or systemic symptoms, it requires immediate medical evaluation.

• Fatigue and Asthenia: A general sense of tiredness or lack of energy.
• Insomnia: Difficulty falling or staying asleep.
• Dyslipidemia: An increase in blood fats, including cholesterol and triglycerides. Your doctor will monitor these levels via regular blood tests.
• Hyperglycemia: Increased blood sugar levels. Patients with pre-existing diabetes may find their condition harder to manage while on Darunavir.

• Lipodystrophy: Changes in body fat distribution, including loss of fat from the face and limbs (lipoatrophy) and accumulation of fat in the abdomen or back of the neck ('buffalo hump').
• Immune Reconstitution Inflammatory Syndrome (IRIS): As the immune system gets stronger, it may overreact to hidden or previous infections (like tuberculosis or fungal infections), causing an inflammatory response.
• Osteonecrosis: Bone tissue death, often in the hip, which can cause joint pain and difficulty moving.

> Warning: Stop taking Darunavir Hydrate and call your doctor immediately if you experience any of these serious reactions.

1. 1Severe Skin Reactions: Darunavir can cause life-threatening skin conditions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Symptoms include blistering, peeling skin, sores in the mouth, and high fever.
2. 2Hepatotoxicity (Liver Damage): Signs include yellowing of the skin or eyes (jaundice), dark-colored urine, light-colored stools, and pain on the right side of the abdomen. Drug-induced hepatitis has been reported, particularly in patients with pre-existing Hepatitis B or C.
3. 3Severe Allergic Reactions: Anaphylaxis (swelling of the face, tongue, or throat; difficulty breathing; rapid heart rate).
4. 4Pancreatitis: Inflammation of the pancreas, characterized by severe upper stomach pain that radiates to the back, accompanied by nausea.

• Metabolic Changes: Long-term use of protease inhibitors like Darunavir is associated with an increased risk of developing Type 2 diabetes and cardiovascular disease due to chronic elevations in lipids and glucose.
• Kidney Function: While Darunavir itself is not highly nephrotoxic, long-term ART regimens can place strain on the kidneys, necessitating regular monitoring of serum creatinine and GFR (Glomerular Filtration Rate).
• Increased Bleeding: In patients with hemophilia (a bleeding disorder), there have been reports of increased spontaneous bleeding while taking protease inhibitors.

Currently, Darunavir Hydrate does not carry a specific FDA Black Box Warning. However, it does carry 'Warnings and Precautions' of the highest clinical significance regarding Hepatotoxicity and Severe Skin Reactions. The drug label emphasizes that patients with pre-existing liver dysfunction, including chronic active hepatitis B or C, have an increased risk for liver function abnormalities and should be monitored with frequent laboratory testing.

Report any unusual symptoms to your healthcare provider. Early detection of side effects is key to maintaining a successful long-term HIV treatment plan.

Darunavir Hydrate is a potent medication that requires careful management. It is only effective when taken as part of a complete antiretroviral regimen. Missing doses can lead to 'viral escape,' where the virus begins to replicate again and develops mutations that make it resistant not only to Darunavir but potentially to other drugs in the same class.

No FDA black box warnings for Darunavir Hydrate. However, clinicians treat the warnings for hepatotoxicity and severe skin reactions with equivalent gravity.

• Sulfa Allergy: Darunavir contains a sulfonamide moiety (a specific chemical structure). If you have a known 'sulfa' allergy, you must inform your doctor. While many patients with sulfa allergies tolerate Darunavir, there is a theoretical risk of cross-reactivity, and you should be monitored for rash.
• Hepatotoxicity: Clinical hepatitis and even liver failure have occurred in patients taking Darunavir. This risk is highest in those with co-infections like Hepatitis B (HBV) or Hepatitis C (HCV). Liver function tests (LFTs) must be performed before starting treatment and periodically thereafter.
• Severe Skin Reactions: Discontinue Darunavir immediately if a rash develops and is accompanied by systemic symptoms (fever, malaise, muscle aches) or blistering. These can be precursors to Stevens-Johnson Syndrome.
• Diabetes and Hyperglycemia: Protease inhibitors can cause new-onset diabetes mellitus or the exacerbation of existing diabetes. In some cases, diabetic ketoacidosis has occurred. Patients may require adjustments to their insulin or oral hypoglycemic medications.
• Fat Redistribution: Patients should be aware that their body shape may change due to fat redistribution, though the long-term health consequences of this are not fully understood.
• Immune Reconstitution Inflammatory Syndrome (IRIS): During the initial phase of treatment, the immune system may respond to indolent (quiet) infections, requiring further diagnostic workup and treatment of the underlying infection.

To ensure safety and efficacy, your healthcare provider will require regular blood work:

1. 1Viral Load (HIV-1 RNA): To check if the virus is being suppressed.
2. 2CD4+ Cell Count: To monitor immune system recovery.
3. 3Liver Function Tests (ALT, AST, Bilirubin): Essential for detecting early signs of liver stress.
4. 4Lipid Panel: Monitoring for increases in cholesterol and triglycerides.
5. 5Blood Glucose/HbA1c: To screen for the development of diabetes.

Darunavir Hydrate generally does not cause sedation or dizziness that would impair the ability to drive. However, some patients report fatigue or headaches. You should observe how the medication affects you before engaging in activities that require mental alertness.

There is no direct contraindication between alcohol and Darunavir Hydrate. However, both alcohol and Darunavir are processed by the liver. Excessive alcohol consumption can increase the risk of liver toxicity and may interfere with your ability to adhere to your medication schedule.

Never stop taking Darunavir Hydrate without consulting your doctor. If you stop the medication, the virus will likely rebound quickly. If you must stop due to a severe side effect, your doctor will need to manage the transition to a new regimen carefully to prevent the development of drug resistance.

> Important: Discuss all your medical conditions, especially liver disease, diabetes, or bleeding disorders, with your healthcare provider before starting Darunavir Hydrate.

Darunavir Hydrate, when boosted with ritonavir or cobicistat, is a powerful inhibitor of the CYP3A enzyme. This means it can cause other drugs to build up to dangerous or fatal levels in your body. The following drugs must NEVER be used with Darunavir:

• Lurasidone and Pimozide: Risk of serious heart rhythm problems (arrhythmias).
• Ergot Derivatives (Ergotamine, Dihydroergotamine): Risk of 'ergotism,' which causes severe constriction of blood vessels, potentially leading to gangrene.
• Lovastatin and Simvastatin: Risk of severe muscle breakdown (rhabdomyolysis) and kidney failure.
• Rifampin: This drug is a potent inducer that will lower Darunavir levels so much that the HIV treatment will fail.
• St. John's Wort: This herbal supplement significantly reduces Darunavir concentrations.
• Sildenafil (Revatio): When used for pulmonary arterial hypertension, this combination is contraindicated due to the risk of dangerously low blood pressure.

• Anticoagulants (Warfarin, Rivaroxaban, Apixaban): Darunavir can change how these drugs work, increasing the risk of life-threatening bleeding. Frequent monitoring of clotting factors (INR) is required.
• Anticonvulsants (Phenytoin, Carbamazepine): These can lower Darunavir levels, while Darunavir can increase the levels of the seizure medication.
• Corticosteroids (Fluticasone, Budesonide): Even inhaled or nasal sprays can be affected, leading to Cushing's Syndrome (excess cortisol) because Darunavir prevents the steroid from being cleared from the body.

• Oral Contraceptives: Darunavir can decrease the effectiveness of birth control pills. Patients should use a backup method, such as condoms, to prevent pregnancy.
• Erectile Dysfunction Drugs (Sildenafil, Tadalafil, Vardenafil): Levels of these drugs are greatly increased. Doses must be significantly reduced (e.g., no more than 25 mg of sildenafil in 48 hours) to avoid severe side effects like low blood pressure and prolonged erections.

• Grapefruit and Grapefruit Juice: These can further inhibit CYP3A4, potentially increasing Darunavir levels and the risk of side effects. It is best to avoid large amounts of grapefruit while on this medication.
• High-Fat Meals: While food is required for absorption, extremely high-fat meals may slightly alter the rate of absorption, though this is generally not clinically significant as long as food is present.

• Garlic Supplements: Large doses of garlic may potentially reduce the plasma concentrations of protease inhibitors.
• Red Yeast Rice: Contains natural statins that can interact similarly to simvastatin, increasing the risk of muscle damage.

Darunavir can cause asymptomatic elevations in serum amylase or lipase. It may also cause false-positive results in certain urine glucose tests if the patient has developed drug-induced hyperglycemia.

For each interaction, the management strategy usually involves either avoiding the second drug, adjusting the dose of the second drug, or intensive monitoring of blood levels and clinical symptoms.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins.

There are several scenarios where Darunavir Hydrate must NEVER be used because the risks far outweigh any potential benefits:

1. 1Hypersensitivity: Any patient with a documented history of severe allergic reaction (anaphylaxis, SJS) to Darunavir or any of its excipients (inactive ingredients) must not take the drug.
2. 2Severe Hepatic Impairment: Patients classified as Child-Pugh Class C have severely compromised liver function. Because Darunavir is primarily metabolized by the liver, it can accumulate to toxic levels and further damage the organ.
3. 3Co-administration with Potent CYP3A Inducers: Drugs like Rifampin or the herb St. John's Wort induce (speed up) the enzymes that break down Darunavir. This leads to sub-therapeutic drug levels, which almost guarantees the development of HIV drug resistance and treatment failure.
4. 4Co-administration with Narrow Therapeutic Index CYP3A Substrates: Drugs where a small increase in concentration leads to toxicity (e.g., Midazolam, Triazolam, Alfuzosin) are strictly contraindicated.

Relative contraindications require a careful risk-benefit analysis by a specialist:

• Mild-to-Moderate Liver Disease: Requires frequent monitoring of liver enzymes.
• Hemophilia: There is an increased risk of spontaneous bleeding, though the mechanism is not well understood. The drug can be used, but the patient must be monitored for hematomas and joint bleeds.
• Sulfa Allergy: While not an absolute contraindication, it requires caution. If a patient has had a life-threatening reaction to sulfa drugs, Darunavir should be avoided unless no other options exist.

Patients who have had severe skin rashes from other protease inhibitors (like Fosamprenavir or Tipranavir) should be treated with extreme caution, as there may be cross-sensitivity in how the body reacts to these chemically related structures.

> Important: Your healthcare provider will evaluate your complete medical history, including past drug allergies and liver health, before prescribing Darunavir Hydrate.

Darunavir Hydrate is an important component of HIV management during pregnancy to prevent mother-to-child transmission.

• Pharmacokinetics in Pregnancy: During the second and third trimesters, the levels of Darunavir in the blood naturally decrease. Therefore, once-daily dosing (800 mg) is NOT recommended for pregnant individuals. Instead, a twice-daily regimen (600 mg with 100 mg ritonavir) is typically used to ensure drug levels remain high enough to suppress the virus.
• Risks: There is no evidence of increased birth defects in humans based on the Antiretroviral Pregnancy Registry data. However, the booster cobicistat is not recommended during pregnancy due to low drug levels.

In the United States and other regions where clean water and infant formula are accessible, the CDC and health authorities recommend that individuals with HIV avoid breastfeeding to eliminate the risk of postnatal HIV transmission. Additionally, it is known that Darunavir is excreted in the milk of lactating rats; it is likely excreted in human milk, and the effects on a nursing infant are unknown.

Darunavir is approved for children 3 years and older. It is not used in children younger than 3 because animal studies showed a high rate of mortality (death) in juvenile rats exposed to Darunavir, likely due to an immature blood-brain barrier and liver enzyme system. In older children, the drug is effective, but weight-based dosing must be strictly followed.

Patients over 65 may be at higher risk for side effects due to age-related declines in liver and kidney function. There is also a higher likelihood of polypharmacy (taking many medications), which increases the risk of dangerous drug interactions. Clinical monitoring should be more frequent in this population.

Darunavir is not significantly cleared by the kidneys. For patients with a GFR above 30 mL/min, no adjustment is needed. For those on dialysis, Darunavir is not expected to be removed by the procedure because it is highly protein-bound. Dosing remains the same, but the overall health of the patient must be monitored.

• Child-Pugh A (Mild): No adjustment.
• Child-Pugh B (Moderate): No adjustment, but use with caution.
• Child-Pugh C (Severe): Contraindicated.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure both the safety of the patient and the suppression of the virus.

Darunavir Hydrate is a non-peptidic HIV-1 protease inhibitor. It was specifically designed to form robust hydrogen bonds with the backbone of the HIV-1 protease enzyme. By binding to the enzyme's active site, it prevents the cleavage of Gag and Gag-Pol polyproteins. This inhibition results in the production of immature viral particles that lack the structural integrity and enzymatic machinery (like reverse transcriptase and integrase) needed to infect new host cells. Its unique structure allows it to maintain effectiveness against many viral strains that have developed resistance to older protease inhibitors like Saquinavir or Indinavir.

The relationship between the concentration of Darunavir and the suppression of HIV is well-established. The goal of therapy is to maintain a 'trough' concentration (the lowest level before the next dose) that is significantly higher than the EC50 (the concentration needed to inhibit 50% of the virus). Because Darunavir is 'boosted,' it provides a high genetic barrier to resistance, meaning the virus would need to develop multiple specific mutations simultaneously to overcome the drug's effect.

| Parameter | Value (Boosted with Ritonavir) |

|---|---|

| Bioavailability | ~37% (increases with food/booster) |

| Protein Binding | 95% (primarily to AAG) |

| Half-life | 15 hours |

| Tmax | 2.5 to 4 hours |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Fecal 79.5%, Renal 13.9% |

• Molecular Formula: C27H37N3O7S (as Darunavir)
• Molecular Weight: 547.66 g/mol
• Solubility: Very slightly soluble in water; solubility increases in organic solvents.
• Structure: It contains a bis-tetrahydrofuran (bis-THF) moiety which is responsible for its high affinity for the protease enzyme.

Darunavir Hydrate is classified as an Antiretroviral, specifically a Protease Inhibitor (PI). It is often grouped with other PIs such as Atazanavir, Lopinavir, and Ritonavir, though it is considered more potent against resistant strains.